David J Couper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4461205/publications.pdf

Version: 2024-02-01

		136950	102487
87	4,806	32	66
papers	citations	h-index	g-index
89	89	89	7701
all docs	docs citations	times ranked	citing authors
un doco	does citations	times funced	ording addition

#	Article	IF	CITATIONS
1	Comparative Impact of Depressive Symptoms and FEV ₁ % on Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2022, 19, 171-178.	3.2	7
2	Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD. Chest, 2022, 161, 949-959.	0.8	6
3	Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD. Chest, 2022, 161, 1239-1249.	0.8	20
4	Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study: Study Design. American Journal of Epidemiology, 2022, 191, 1153-1173.	3.4	11
5	Reconsidering the Utility of Race-Specific Lung Function Prediction Equations. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 819-829.	5.6	63
6	Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR. Science of the Total Environment, 2022, 829, 154694.	8.0	9
7	Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study. European Heart Journal, 2022, 43, 2196-2208.	2.2	12
8	Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 987-997.	5.6	38
9	Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 957-968.	5.6	71
10	Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 277-291.	0.7	1
11	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 326-335.	0.7	O
12	Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. Npj Biofilms and Microbiomes, 2021, 7, 14.	6.4	33
13	The influence of social support on COPD outcomes mediated by depression. PLoS ONE, 2021, 16, e0245478.	2.5	8
14	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. Scientific Reports, 2021, 11, 4916.	3.3	12
15	Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. Respiratory Research, 2021, 22, 126.	3.6	14
16	Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD. Respiratory Research, 2021, 22, 127.	3.6	26
17	Disparities in access to food and chronic obstructive pulmonary disease (COPD)-related outcomes: a cross-sectional analysis. BMC Pulmonary Medicine, 2021, 21, 139.	2.0	5
18	Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Genome Medicine, 2021, 13, 66.	8.2	21

#	Article	IF	Citations
19	Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). International Journal of COPD, 2021, Volume 16, 1477-1496.	2.3	8
20	Ratio of FEV1/Slow Vital Capacity ofÂ< 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function. Chest, 2021, 160, 94-103.	0.8	8
21	Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC Study. JNCI Cancer Spectrum, 2021, 5, pkab080.	2.9	6
22	Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study. Lancet Respiratory Medicine, the, 2020, 8, 34-44.	10.7	96
23	The Effects of Rare <i>SERPINA1</i> Variants on Lung Function and Emphysema in SPIROMICS. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 540-554.	5.6	38
24	A general framework for integrative analysis of incomplete multiomics data. Genetic Epidemiology, 2020, 44, 646-664.	1.3	9
25	<p>Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the Spiromics Cohort</p> . International Journal of COPD, 2020, Volume 15, 1887-1898.	2.3	2
26	Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. JAMA - Journal of the American Medical Association, 2020, 323, 2268.	7.4	104
27	Longitudinal Associations Between Body Mass Index During Young Adulthood, Subsequent Weight Change, and Incident Diabetes During Mid- and Older-Adulthood in Non-Hispanic White and African American Populations: The Atherosclerosis Risk in Communities Study. Metabolic Syndrome and Related Disorders. 2020. 18. 313-320.	1.3	6
28	Association of Nonobstructive Chronic Bronchitis With Respiratory Health Outcomes in Adults. JAMA Internal Medicine, 2020, 180, 676.	5.1	33
29	Associations Among 25-Hydroxyvitamin DÂLevels, Lung Function, and Exacerbation Outcomes in COPD. Chest, 2020, 157, 856-865.	0.8	35
30	Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 370-381.	0.7	5
31	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 473-481.	5.6	1
32	The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study. Angiology, 2019, 70, 130-140.	1.8	18
33	Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). Respiratory Research, 2019, 20, 153.	3.6	25
34	Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS. European Respiratory Journal, 2019, 54, 1802214.	6.7	29
35	Aspirin Use and Respiratory Morbidity in COPD. Chest, 2019, 155, 519-527.	0.8	25
36	Discriminative Accuracy of FEV ₁ :FVC Thresholds for COPD-Related Hospitalization and Mortality. JAMA - Journal of the American Medical Association, 2019, 321, 2438.	7.4	135

#	Article	IF	Citations
37	Gumbel regression models for a monotone increasing continuous biomarker subject to measurement error. Journal of Statistical Planning and Inference, 2019, 203, 160-168.	0.6	4
38	Reproducibility and Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer Assay. journal of applied laboratory medicine, The, 2019, 4, 30-39.	1.3	61
39	A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 721-731.	5.6	40
40	Systemic Markers of Inflammation in Smokers With Symptoms Despite PreservedÂSpirometry in SPIROMICS. Chest, 2019, 155, 908-917.	0.8	18
41	The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS. Respiratory Research, 2019, 20, 254.	3.6	8
42	<p>Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis</p> . International Journal of COPD, 2019, Volume 14, 2927-2938.	2.3	16
43	Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS. Annals of the American Thoracic Society, 2019, 16, 200-208.	3.2	31
44	Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy. Annals of the American Thoracic Society, 2019, 16, 439-446.	3.2	18
45	Human airway branch variation and chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E974-E981.	7.1	80
46	Enhancing the Infrastructure of the Atherosclerosis Risk in Communities (ARIC) Study for Cancer Epidemiology Research: ARIC Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 295-305.	2.5	32
47	Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort. Annals of the American Thoracic Society, 2018, 15, 808-816.	3.2	32
48	Prospective study of lung function and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study. Atherosclerosis, 2018, 268, 225-230.	0.8	10
49	Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort. Journal of Allergy and Clinical Immunology, 2018, 141, 429-432.	2.9	12
50	Academic chartered data safety committees versus industry sponsored data safety committees: The need for different recommendations. Clinical Trials, 2018, 15, 212-213.	1.6	1
51	Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 499-507.	3.7	75
52	Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Respiratory Research, 2018, 19, 178.	3.6	20
53	Association of monocyte myeloperoxidase with incident cardiovascular disease: The Atherosclerosis Risk in Communities Study. PLoS ONE, 2018, 13, e0205310.	2.5	10
54	Genome-wide association study of lung function and clinical implication in heavy smokers. BMC Medical Genetics, 2018, 19, 134.	2.1	28

#	Article	IF	CITATIONS
55	Harmonization of Respiratory Data From 9 US Population-Based Cohorts. American Journal of Epidemiology, 2018, 187, 2265-2278.	3.4	46
56	Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. Annals of the American Thoracic Society, 2018, 15, 710-717.	3.2	32
57	NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. Respiratory Medicine, 2018, 140, 87-93.	2.9	18
58	Genetic evidence of assortative mating in humans. Nature Human Behaviour, 2017, 1, .	12.0	242
59	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Annals of the American Thoracic Society, 2017, 14. 636-642.	3.2	30
60	Differentiation of quantitative CT imaging phenotypes in asthma versus COPD. BMJ Open Respiratory Research, 2017, 4, e000252.	3.0	30
61	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine, the, 2017, 5, 956-967.	10.7	211
62	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine, the, 2017, 5, 619-626.	10.7	219
63	Milk Intake at Midlife and Cognitive Decline over 20 Years. The Atherosclerosis Risk in Communities (ARIC) Study. Nutrients, 2017, 9, 1134.	4.1	28
64	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. PLoS ONE, 2017, 12, e0184606.	2.5	20
65	A controlled statistical study to assess measurement variability as a function of test object position and configuration for automated surveillance in a multicenter longitudinal COPD study (SPIROMICS). Medical Physics, 2016, 43, 2598-2610.	3.0	6
66	Longitudinal Patterns of Change in Systolic Blood Pressure and Incidence of Cardiovascular Disease. Hypertension, 2016, 67, 1150-1156.	2.7	37
67	Age-Related Differences in Health-Related Quality of Life in COPD. Chest, 2016, 149, 927-935.	0.8	41
68	Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. New England Journal of Medicine, 2016, 374, 1811-1821.	27.0	526
69	Synergistic and Non-synergistic Associations for Cigarette Smoking and Non-tobacco Risk Factors for Cardiovascular Disease Incidence in the Atherosclerosis Risk In Communities (ARIC) Study. Nicotine and Tobacco Research, 2016, 19, ntw235.	2.6	13
70	SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 794-806.	5.6	180
71	Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis, 2016, 253, 156-163.	0.8	15
72	Lung function decline over 25 years of follow-up among black and white adults in the ARIC study cohort. Respiratory Medicine, 2016, 113, 57-64.	2.9	23

#	Article	IF	CITATIONS
73	Trans-ethnic Meta-analysis and Functional Annotation Illuminates theÂGenetic Architecture of Fasting Glucose and Insulin. American Journal of Human Genetics, 2016, 99, 56-75.	6.2	55
74	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genetics, 2016, 12, e1006011.	3.5	88
75	Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Journal of Translational Medicine, 2015, 13, 19.	4.4	41
76	Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney International, 2015, 87, 820-827.	5.2	96
77	Abstract 10804: Incidence and Prognostic Significance of Silent Versus Clinically Manifest Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2015, 132, .	1.6	0
78	Abstract 18914: Comparison of Statin Eligibility Using the Pooled Cohort Equations, ATP-III Framingham and Reynolds Risk Scores Among Adults Who Experienced ASCVD Events: The Atherosclerosis Risk in Communities Study. Circulation, 2015, 132, .	1.6	0
79	Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): TableÂ1. Thorax, 2014, 69, 492-495.	5.6	277
80	Diabetes in Midlife and Cognitive Change Over 20 Years. Annals of Internal Medicine, 2014, 161, 785.	3.9	325
81	B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace, 2014, 16, 1426-1433.	1.7	144
82	Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax, 2014, 69, 987-996.	5 . 6	114
83	Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. Journal of Translational Medicine, 2014, 12, 9.	4.4	46
84	Impact of Differential Attrition on the Association of Education With Cognitive Change Over 20 Years of Follow-up: The ARIC Neurocognitive Study. American Journal of Epidemiology, 2014, 179, 956-966.	3.4	102
85	Meta-analysis of loci associated with age at natural menopause in African-American women. Human Molecular Genetics, 2014, 23, 3327-3342.	2.9	54
86	The Periodontitis and Vascular Events (PAVE) Pilot Study: Recruitment, Retention, and Community Care Controls. Journal of Periodontology, 2008, 79, 80-89.	3.4	34
87	Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. Journal of Clinical Epidemiology, 2003, 56, 880-890.	5.0	276